Resmed (ASX:RMD) reported Friday fiscal second-quarter earnings of $2.43 per diluted share on a non-GAAP basis, up from $1.88 per diluted share a year earlier.
Analysts polled by Visible Alpha expected $2.32 per diluted share.
Revenue for the three months ended Dec. 31, 2024, rose 10% to $1.28 billion from $1.16 billion a year earlier. Analysts surveyed by Visible Alpha expected $1.27 billion.
The board declared a quarterly cash dividend of $0.53 per share, with a record date of Feb. 13, payable on March 20. This is up from the previously reported period's dividend of $0.48.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。